Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Alessandro Zerbi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9176-0448; OpenAlex author ID A5043785467, A5072356061, A5132713498. Sources: OpenAlex.

Their work

Papers
69 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
249
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: 4 papers · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: 5 papers · 2021: 6 papers · 2022: 3 papers · 2023: 17 papers · 2024: 7 papers · 2025: 6 papers · 2026: 9 papers

Papers 50 of 69

  1. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  2. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  3. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  4. Metabolomic profiling of pancreatic juice: a potential prognostic tool for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.suronc.2026.102456↗
  5. The TGF-βR1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization. Co-author DOI 10.1038/s41419-026-08581-9↗
  6. The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-25-4154↗
  7. Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive T… Co-author DOI 10.1158/2326-6066.cir-25-1602↗
  8. Futility in adenosquamous pancreatic cancer. Co-author DOI 10.1186/s12957-026-04351-1↗
  9. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18479-z↗
  10. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  11. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  12. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  13. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  14. Carbohydrate antigens Lewis a and Lewis b act as tumor markers cooperating with CA19.9 in the management of PDAC patients. Co-author DOI 10.1016/j.cca.2024.119990↗
  15. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18212-w↗
  16. Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.02.017↗
  17. Minimally invasive versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma: an entropy balancing analysis. Co-author DOI 10.1016/j.hpb.2023.09.013↗
  18. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  19. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-023-14805-5↗
  20. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  21. Depicting the cellular complexity of pancreatic adenocarcinoma by Imaging Mass Cytometry: focus on cancer-associated fibroblasts. Co-author DOI 10.3389/fimmu.2024.1472433↗
  22. Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups. Co-author DOI 10.3389/fonc.2024.1405612↗
  23. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis? Last author DOI 10.1007/s13304-023-01628-y↗
  24. Familial pancreatic cancer. Co-author DOI 10.1016/j.clinre.2023.102079↗
  25. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  26. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment. Co-author DOI 10.1016/j.ejso.2022.12.006↗
  27. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  28. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Last author DOI 10.1016/j.surg.2023.01.016↗
  29. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  30. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  31. Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells. Co-author DOI 10.1136/gutjnl-2021-325811↗
  32. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  33. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  34. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  35. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  36. Independent effect of fat-to-muscle mass ratio at bioimpedance analysis on long-term survival in patients receiving surgery for pancreatic cancer. Co-author DOI 10.3389/fnut.2023.1118616↗
  37. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  38. Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/curroncol30040282↗
  39. Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity … Co-author DOI 10.3390/curroncol30070513↗
  40. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival. Last author DOI 10.1016/j.dld.2021.06.006↗
  41. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2022.05.006↗
  42. Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreati… Co-author DOI 10.3390/cancers14112653↗
  43. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectabili… Co-author DOI 10.1097/as9.0000000000000087↗
  44. The Immune Landscape in a Long-Term Survival Pancreatic Adenocarcinoma Patient Highly Responsive to a Multidisciplinary Approach With Chemo-Radio Treatments. Last author DOI 10.1097/mpa.0000000000001907↗
  45. Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Pr… Co-author DOI 10.1097/sla.0000000000003717↗
  46. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  47. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  48. Borderline resectable pancreatic cancer: Certainties and controversies. Last author DOI 10.4240/wjgs.v13.i6.516↗
  49. Pancreatic Cancer Cells Require the Transcription Factor MYRF to Maintain ER Homeostasis. Co-author DOI 10.1016/j.devcel.2020.09.011↗
  50. Italian registry of families at risk of pancreatic cancer: AISP Familial Pancreatic Cancer Study Group. Co-author DOI 10.1016/j.dld.2020.07.027↗

Closest collaborators

The 25 strongest of 249 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gennaro Nappo · 16 shared papers, 2017–2026 · strength 2.74
  2. Giovanni Luigi Capretti · 18 shared papers, 2016–2026 · strength 2.53
  3. Riccardo Casadei · 10 shared papers, 2020–2026 · strength 1.42
  4. Massimo Falconi · 12 shared papers, 2012–2026 · strength 1.41
  5. Roberto Salvia · 11 shared papers, 2019–2026 · strength 1.40
  6. Federica Marchesi · 10 shared papers, 2016–2026 · strength 1.36
  7. Ugo Boggi · 9 shared papers, 2020–2026 · strength 1.29
  8. Francesca Gavazzi · 10 shared papers, 2016–2026 · strength 1.22
  9. Silvia Bozzarelli · 7 shared papers, 2022–2026 · strength 1.21
  10. Marialuisa Barbagallo · 7 shared papers, 2020–2026 · strength 1.13
  11. Salvatore Paiella · 8 shared papers, 2019–2026 · strength 1.08
  12. Giuseppe Malleo · 9 shared papers, 2016–2026 · strength 1.05
  13. Greta Donisi · 6 shared papers, 2020–2026 · strength 1.01
  14. Marc G. Besselink · 6 shared papers, 2020–2026 · strength 0.85
  15. Claudio Bassi · 8 shared papers, 2012–2024 · strength 0.83
  16. Matteo De Pastena · 6 shared papers, 2020–2026 · strength 0.79
  17. Giovanni Butturini · 7 shared papers, 2019–2024 · strength 0.76
  18. Silvia Carrara · 6 shared papers, 2019–2024 · strength 0.76
  19. Emanuele F. Kauffmann · 4 shared papers, 2023–2026 · strength 0.72
  20. Erica Secchettin · 5 shared papers, 2020–2026 · strength 0.71
  21. Luca Vittorio Gianotti · 5 shared papers, 2021–2023 · strength 0.66
  22. Luigi Laghi · 5 shared papers, 2012–2026 · strength 0.64
  23. Nina Cortese · 6 shared papers, 2016–2024 · strength 0.61
  24. Giuseppe Riccardo Diaferia · 5 shared papers, 2016–2024 · strength 0.61
  25. Gioacchino Natoli · 5 shared papers, 2016–2024 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.